Cargando…

Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents

Di(2-pyridyl)ketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) and di(2-pyridyl)ketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC) are novel, highly potent and selective anti-tumor and anti-metastatic drugs. Despite their structural similarity, these agents differ in their efficacy and toxicity i...

Descripción completa

Detalles Bibliográficos
Autores principales: Sestak, Vit, Stariat, Jan, Cermanova, Jolana, Potuckova, Eliska, Chladek, Jaroslav, Roh, Jaroslav, Bures, Jan, Jansova, Hana, Prusa, Petr, Sterba, Martin, Micuda, Stanislav, Simunek, Tomas, Kalinowski, Danuta S., Richardson, Des R., Kovarikova, Petra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767442/
https://www.ncbi.nlm.nih.gov/pubmed/26623727
_version_ 1782417814969122816
author Sestak, Vit
Stariat, Jan
Cermanova, Jolana
Potuckova, Eliska
Chladek, Jaroslav
Roh, Jaroslav
Bures, Jan
Jansova, Hana
Prusa, Petr
Sterba, Martin
Micuda, Stanislav
Simunek, Tomas
Kalinowski, Danuta S.
Richardson, Des R.
Kovarikova, Petra
author_facet Sestak, Vit
Stariat, Jan
Cermanova, Jolana
Potuckova, Eliska
Chladek, Jaroslav
Roh, Jaroslav
Bures, Jan
Jansova, Hana
Prusa, Petr
Sterba, Martin
Micuda, Stanislav
Simunek, Tomas
Kalinowski, Danuta S.
Richardson, Des R.
Kovarikova, Petra
author_sort Sestak, Vit
collection PubMed
description Di(2-pyridyl)ketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) and di(2-pyridyl)ketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC) are novel, highly potent and selective anti-tumor and anti-metastatic drugs. Despite their structural similarity, these agents differ in their efficacy and toxicity in-vivo. Considering this, a comparison of their pharmacokinetic and pharmaco/toxico-dynamic properties was conducted to reveal if these factors are involved in their differential activity. Both compounds were administered to Wistar rats intravenously (2 mg/kg) and their metabolism and disposition were studied using UHPLC-MS/MS. The cytotoxicity of both thiosemicarbazones and their metabolites was also examined using MCF-7, HL-60 and HCT116 tumor cells and 3T3 fibroblasts and H9c2 cardiac myoblasts. Their intracellular iron-binding ability was characterized by the Calcein-AM assay and their iron mobilization efficacy was evaluated. In contrast to DpC, Dp44mT undergoes rapid demethylation in-vivo, which may be related to its markedly faster elimination (T(1/2) = 1.7 h for Dp44mT vs. 10.7 h for DpC) and lower exposure. Incubation of these compounds with cancer cells or cardiac myoblasts did not result in any significant metabolism in-vitro. The metabolism of Dp44mT in-vivo resulted in decreased anti-cancer activity and toxicity. In conclusion, marked differences in the pharmacology of Dp44mT and DpC were observed and highlight the favorable pharmacokinetics of DpC for cancer treatment.
format Online
Article
Text
id pubmed-4767442
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-47674422016-03-25 Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents Sestak, Vit Stariat, Jan Cermanova, Jolana Potuckova, Eliska Chladek, Jaroslav Roh, Jaroslav Bures, Jan Jansova, Hana Prusa, Petr Sterba, Martin Micuda, Stanislav Simunek, Tomas Kalinowski, Danuta S. Richardson, Des R. Kovarikova, Petra Oncotarget Priority Research Paper Di(2-pyridyl)ketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) and di(2-pyridyl)ketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC) are novel, highly potent and selective anti-tumor and anti-metastatic drugs. Despite their structural similarity, these agents differ in their efficacy and toxicity in-vivo. Considering this, a comparison of their pharmacokinetic and pharmaco/toxico-dynamic properties was conducted to reveal if these factors are involved in their differential activity. Both compounds were administered to Wistar rats intravenously (2 mg/kg) and their metabolism and disposition were studied using UHPLC-MS/MS. The cytotoxicity of both thiosemicarbazones and their metabolites was also examined using MCF-7, HL-60 and HCT116 tumor cells and 3T3 fibroblasts and H9c2 cardiac myoblasts. Their intracellular iron-binding ability was characterized by the Calcein-AM assay and their iron mobilization efficacy was evaluated. In contrast to DpC, Dp44mT undergoes rapid demethylation in-vivo, which may be related to its markedly faster elimination (T(1/2) = 1.7 h for Dp44mT vs. 10.7 h for DpC) and lower exposure. Incubation of these compounds with cancer cells or cardiac myoblasts did not result in any significant metabolism in-vitro. The metabolism of Dp44mT in-vivo resulted in decreased anti-cancer activity and toxicity. In conclusion, marked differences in the pharmacology of Dp44mT and DpC were observed and highlight the favorable pharmacokinetics of DpC for cancer treatment. Impact Journals LLC 2015-11-25 /pmc/articles/PMC4767442/ /pubmed/26623727 Text en Copyright: © 2015 Sestak et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Priority Research Paper
Sestak, Vit
Stariat, Jan
Cermanova, Jolana
Potuckova, Eliska
Chladek, Jaroslav
Roh, Jaroslav
Bures, Jan
Jansova, Hana
Prusa, Petr
Sterba, Martin
Micuda, Stanislav
Simunek, Tomas
Kalinowski, Danuta S.
Richardson, Des R.
Kovarikova, Petra
Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents
title Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents
title_full Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents
title_fullStr Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents
title_full_unstemmed Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents
title_short Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents
title_sort novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents
topic Priority Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767442/
https://www.ncbi.nlm.nih.gov/pubmed/26623727
work_keys_str_mv AT sestakvit novelandpotentantitumorandantimetastaticdi2pyridylketonethiosemicarbazonesdemonstratemarkeddifferencesinpharmacologybetweenthefirstandsecondgenerationleadagents
AT stariatjan novelandpotentantitumorandantimetastaticdi2pyridylketonethiosemicarbazonesdemonstratemarkeddifferencesinpharmacologybetweenthefirstandsecondgenerationleadagents
AT cermanovajolana novelandpotentantitumorandantimetastaticdi2pyridylketonethiosemicarbazonesdemonstratemarkeddifferencesinpharmacologybetweenthefirstandsecondgenerationleadagents
AT potuckovaeliska novelandpotentantitumorandantimetastaticdi2pyridylketonethiosemicarbazonesdemonstratemarkeddifferencesinpharmacologybetweenthefirstandsecondgenerationleadagents
AT chladekjaroslav novelandpotentantitumorandantimetastaticdi2pyridylketonethiosemicarbazonesdemonstratemarkeddifferencesinpharmacologybetweenthefirstandsecondgenerationleadagents
AT rohjaroslav novelandpotentantitumorandantimetastaticdi2pyridylketonethiosemicarbazonesdemonstratemarkeddifferencesinpharmacologybetweenthefirstandsecondgenerationleadagents
AT buresjan novelandpotentantitumorandantimetastaticdi2pyridylketonethiosemicarbazonesdemonstratemarkeddifferencesinpharmacologybetweenthefirstandsecondgenerationleadagents
AT jansovahana novelandpotentantitumorandantimetastaticdi2pyridylketonethiosemicarbazonesdemonstratemarkeddifferencesinpharmacologybetweenthefirstandsecondgenerationleadagents
AT prusapetr novelandpotentantitumorandantimetastaticdi2pyridylketonethiosemicarbazonesdemonstratemarkeddifferencesinpharmacologybetweenthefirstandsecondgenerationleadagents
AT sterbamartin novelandpotentantitumorandantimetastaticdi2pyridylketonethiosemicarbazonesdemonstratemarkeddifferencesinpharmacologybetweenthefirstandsecondgenerationleadagents
AT micudastanislav novelandpotentantitumorandantimetastaticdi2pyridylketonethiosemicarbazonesdemonstratemarkeddifferencesinpharmacologybetweenthefirstandsecondgenerationleadagents
AT simunektomas novelandpotentantitumorandantimetastaticdi2pyridylketonethiosemicarbazonesdemonstratemarkeddifferencesinpharmacologybetweenthefirstandsecondgenerationleadagents
AT kalinowskidanutas novelandpotentantitumorandantimetastaticdi2pyridylketonethiosemicarbazonesdemonstratemarkeddifferencesinpharmacologybetweenthefirstandsecondgenerationleadagents
AT richardsondesr novelandpotentantitumorandantimetastaticdi2pyridylketonethiosemicarbazonesdemonstratemarkeddifferencesinpharmacologybetweenthefirstandsecondgenerationleadagents
AT kovarikovapetra novelandpotentantitumorandantimetastaticdi2pyridylketonethiosemicarbazonesdemonstratemarkeddifferencesinpharmacologybetweenthefirstandsecondgenerationleadagents